Indeed, our studies demonstrate that combined inhibition of MEK and CKD4/6 is synergistic in vitro in a variety of KRAS mutant CRC cell lines and yields tumor regression in vivo in cell line xenografts and PDXs of KRAS mutant CRC. This evidence concerns the gene MAP2K7 and neoplasm.